rajasekharkakarla
☆    

India,
2019-09-20 04:35

Posting: # 20628
Views: 728
 

 Reference replicated designs [Regulatives / Guidelines]

Dear All,

As per FDA guidelines "We recommend that if the predose value is greater than 5 percent of Cmax, you drop the subject from all BE study evaluations".

Is it applicable for fully replicated designs also, if i got greater than 5% Cmax in period 4 whether i need to exclude the subject from entire study or can we use available data for Swr calculations if subject completed two reference treatment periods.

Thanks&Regards,
Rajasekhar
Activity
 Admin contact
20,128 posts in 4,245 threads, 1,384 registered users;
online 31 (0 registered, 31 guests [including 7 identified bots]).
Forum time (Europe/Vienna): 22:06 UTC

You really don’t know what you don’t know until you write about it.
Then, everyone knows what you don’t know.    Rod Machado

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5